Offering lifted from $1 million per year to finance approval of Viorra
By Devika Patel
Knoxville, Tenn., Feb. 10 - Easton Pharmaceuticals Inc. said it increased an equity purchase agreement to $5 million per year from $1 million per year. The best-efforts stock sales are being conducted in regulation D offerings.
Proceeds will be used to complete the approval process of Viorra, manufacture and mass market Viorra, start clinical trials for cancer drug XILIVE and expand on the company's medical marijuana initiatives, as well as bring other products into its medical marijuana portfolio.
The Toronto company develops and markets therapeutic and cosmetic health-care products.
| Issuer: | Easton Pharmaceuticals Inc.
|
| Issue: | Equity purchase agreement
|
| Amount: | $5 million per year
|
| Warrants: | No
|
| Upsized: | Feb. 10
|
| Stock symbol: | OTCBB: EAPH
|
| Stock price: | $0.07 at close Feb. 7
|
| Market capitalization: | $4.56 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
